SCHEMBL3091696

SCHEMBL3091696

CN(C)C(=O)Nc1snc(OCCCc2ccccc2)c1C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR2A P27037 1/20 0.42
TGFBR2 P37173 1/20 0.42
LMNA P02545 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
RECQL P46063 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HTT P42858 2/20 0.37
KDR P35968 1/20 0.36
NR3C2 P08235 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
S1PR5 Q9H228 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083668 0.97 ACVR2A (0.41) ACVR2ATGFBR2LMNASIRT2SMN1; SMN2
SCHEMBL3087669 0.95 ACVR2A (0.42) ACVR2ATGFBR2LMNASIRT2SMN1; SMN2
SCHEMBL4851770 0.89 NR3C2 (0.43) ACVR2ATGFBR2SIRT2NPC1RAB9A
SCHEMBL3085453 0.89 ACVR2A (0.42) ACVR2ATGFBR2LMNAALDH1A1HTT
SCHEMBL3072105 0.88 ACVR2A (0.41) ACVR2ATGFBR2SMN1; SMN2NPC1RAB9A
SCHEMBL3073485 0.88 ACVR2A (0.41) ACVR2ATGFBR2SMN1; SMN2RECQLNPC1
SCHEMBL3078380 0.88 ACVR2A (0.50) ACVR2ATGFBR2LMNASMN1; SMN2NPC1
SCHEMBL3084188 0.87 ACVR2A (0.49) ACVR2ATGFBR2NR3C2
SCHEMBL3096057 0.87 RAB9A (0.43) ACVR2ATGFBR2SMN1; SMN2NPC1RAB9A
SCHEMBL3091314 0.84 KDR (0.38) ACVR2ATGFBR2LMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790902-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2010-09-07 US disclosed
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents PFIZER, INC. (US) 2008-12-04 US disclosed
US-7405218-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2008-07-29 US disclosed
EP-1084114-B1 ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-08 EP disclosed
US-20030149048-A1 Isothiazole derivatives useful as anticancer agents PFIZER INC. 2003-08-07 US disclosed
US-6235764-B1 Isothiazole derivatives useful as anticancer agents PFIZER INC. 2001-05-22 US disclosed
EP-1084114-A1 ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2001-03-21 EP disclosed
WO-1999062890-A1 ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents CDKN1A, TK1, CDK1 ACVR2A 2547/4885TGFBR2 1883/4885LMNA 3232/4885
US-20030149048-A1 Isothiazole derivatives useful as anticancer agents TP53, MCL1, ACIN1 ACVR2A 4702/4885TGFBR2 3414/4885LMNA 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.